Vascular Endothelial Growth Factor Receptor-1

Download PDF

Recent Publications on Vascular Endothelial Growth Factor Receptor-1:
Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury. Following trauma to the brain significant changes occur in both the...	18th July, 2008	Department of Anatomy and Regenerative Biology, The George Washington	Exp Neurol. 2008 Jul;212(1):108-17. Epub 2008 Apr 3. DOI Direct Link
Is serum-soluble vascular endothelial growth factor receptor-1 of importance in unexplained infertility? Objective. To analyze the role of vascular endothelial growth factor...	9th July, 2008	Departments of Obstetrics and Gynaecology, Helsinki University Central	Acta Obstet Gynecol Scand. 2008 May 21;:1-7. DOI Direct Link
Vascular Endothelial Growth Factor Receptor-1 Regulates Postnatal Angiogenesis Through Inhibition of the Excessive Activation of Akt. Vascular endothelial growth factor (VEGF) binds both VEGF receptor-1...	28th June, 2008	Department of Cardiovascular Science and Medicine, Chiba University	Circ Res. 2008 Jun 26;. DOI Direct Link
Functional anatomy of normal bile ducts. The biliary tree is a complex network of conduits that begins with the...	28th June, 2008	Department of Internal Medicine, Yale University, New Haven 06504,	Anat Rec (Hoboken). 2008 Jun;291(6):653-60. DOI Direct Link
The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. Blood vessel formation requires the integrated regulation of endothelial...	25th June, 2008	Department of Biology, The University of North Carolina at Chapel Hill,	J Cell Biol. 2008 Jun 2;181(5):847-58. Epub 2008 May 26. DOI Direct Link
→View more research publications.

BioNews Results for Vascular Endothelial Growth Factor Receptor-1:
Crohn's disease: beyond antagonists of tumour necrosis factor	Lancet:  Jul 4 2008 12:44AM Matching: vascular endothelial growth factor receptor 1
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Cal	Journal of the American Medical Association:  Jun 10 2008 9:35PM Matching: vascular endothelial growth factor receptor 1
Cyclacel Pharmaceuticals Presents Insights Into The Mechanisms Of Its Cell Cycle Inhibitor Drugs	BioPortfolio:  May 19 2008 12:25PM Matching: vascular endothelial growth factor receptor 1
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies	PharmCast:  May 16 2008 4:13AM Matching: vascular endothelial growth factor receptor 1

Vascular Endothelial Growth Factor Receptor-1 Clinical Trials:
Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer	Pancreatic Cancer;   Pancreas Neoplasms;   Cancer of Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer

Vascular Endothelial Growth Factor Receptor-1 Patents:
US Patent No.	Title
7393863	Methods of using N-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl- -carboxamide for the treatment and management of myelodysplastic syndromes
6855508	ELISA for VEGF
6846839	Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
6831075	Heterocyclic substituted pyrazolones
6800760	Quinolinone derivatives
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Vascular Endothelial Growth Factor Receptor-1 scientists - we have details of around 134 individuals working on Vascular Endothelial Growth Factor Receptor-1 .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.